基金经理：贺雨轩
| 单位净值:0.9253 | 净值增长率:0.15% | 累计净值:0.9253 | 截止日期:2025/3/28 | ||
|---|---|---|---|---|---|
| 最新估值:-(-) | 涨跌幅:- | 涨跌额:- | |||
| 最新规模:0.48亿元 | 风险等级:高风险 | 申购状态:可申购 | 赎回状态:可赎回 |
展开全部
- 基本资料
- 投资风格
- 基金财务状况
- 基金评级
天弘恒生沪深港创新药精选50ETF发起联接C(014565)申购赎回 |
||||||
|---|---|---|---|---|---|---|
| 报告期 | 期初总份额(份) | 期末总份额(份) | 期间总申购份额(份) | 期间总赎回份额(份) | 期间净申赎份额(份) | 净申赎比例 |
| 2024/12/31 | 55,494,000 | 52,187,500 | 44,492,200 | 47,798,800 | -3,306,600 | -5.96% |
| 2024/9/30 | 59,457,400 | 55,494,000 | 30,955,300 | 34,918,600 | -3,963,300 | -6.67% |
| 2024/6/30 | 65,854,300 | 59,457,400 | 82,944,200 | 89,341,100 | -6,396,900 | -9.71% |
| 2024/6/30 | 58,061,000 | 59,457,400 | 39,038,800 | 37,642,500 | 1,396,300 | 2.4% |
| 2024/3/31 | 65,854,300 | 58,061,000 | 43,905,300 | 51,698,600 | -7,793,300 | -11.83% |
| 2023/12/31 | 12,299,300 | 65,854,300 | 183,508,000 | 129,953,000 | 53,555,000 | 435.43% |
| 2023/12/31 | 43,712,400 | 65,854,300 | 82,424,400 | 60,282,600 | 22,141,800 | 50.65% |
| 2023/9/30 | 33,768,200 | 43,712,400 | 40,267,800 | 30,323,700 | 9,944,100 | 29.45% |
| 2023/6/30 | 12,299,300 | 33,768,200 | 60,816,100 | 39,347,200 | 21,468,900 | 174.55% |
| 2023/6/30 | 19,787,700 | 33,768,200 | 40,260,200 | 26,279,700 | 13,980,500 | 70.65% |
| 2023/3/31 | 12,299,300 | 19,787,700 | 20,555,900 | 13,067,600 | 7,488,300 | 60.88% |
| 2022/12/31 | 5,172,890 | 12,299,300 | 32,709,800 | 25,583,300 | 7,126,500 | 137.77% |
| 2022/12/31 | 13,190,800 | 12,299,300 | 13,045,800 | 13,937,300 | -891,500 | -6.76% |
| 2022/9/30 | 7,161,560 | 13,190,800 | 17,246,900 | 11,217,700 | 6,029,200 | 84.19% |
*注：新浪财经提醒：以上数据由合作伙伴提供，仅供参考，交易请以正式公告数据为准。